World News – Texas Heart University is participating in a study to treat acute respiratory distress syndrome in hospitalized Covid-19 patients

The Texas Heart Institute (THI) has been selected as one of up to 60 locations in the world to participate in an international survey seeking to help COVID-19 patients who develop acute respiratory distress syndrome (ARDS). Dr. Emerson Perrin, a world-recognized cardiologist known for his work in developing stem cell therapies for cardiovascular disease, works as a lead investigator on the study at the Texas Heart Institute.

Sponsored by the Australian regenerative medicine company Mesoblast, studies will begin locally through the Heart and Thoracic Surgery Trials Network at Texas Heart Institute in December 2020. As part of the study – which will focus on the sickest patients – participating ICU patients with COVID-19 acute respiratory distress syndrome will be randomly assigned to receive intravenous infusions from allogeneic stromal sarcoma-based therapy or placebo in addition to maximal care..

According to the Centers for Disease Control and Prevention, up to 85% of ICU patients have acute respiratory distress syndrome, and 20 to 42% of patients hospitalized with COVID-19 develop these complications.. More than 40% of ICU patients diagnosed with acute respiratory distress syndrome die – some studies put the number as high as 72% – and those who survive complications spend 10-13 days in the hospital on average..

“The Texas Heart Institute is eager to participate in a study that has enormous potential to alleviate serious complications of COVID-19 in very sick patients,” Dr.. . Perrin confirmed. He added, « My colleagues and I have been working on cardiac cell therapy for 20 years, and at that time, we saw stem cell treatments dramatically improve lung function. ». . Basically, the lungs act as a filter, and when stem cells are injected intravenously, they end up in the lungs. By taking what we’ve learned from the accumulated data from countless heart patients over the years, we are applying it to COVID-19 patients in order to harness the power of cells to reduce inflammation in the lungs in individuals who have few other treatment options..

Mesoblast’s remestemcel-L, an intravenous (IV) infusion of allogeneic mesenchymal stem cells (MSCs) has been used previously in other clinical settings with positive results. At Mount Sinai Hospital in New York, researchers observed an 83% survival rate in patients with COVID-19 infection who relied on ventilator support after treatment with remestemcel-L under emergency compassionate use.. Within ten days of treatment, 75% no longer needed ventilator support. Shortly thereafter, 7 of the 12 patients were discharged from the hospital. The Texas Heart Institute will now use the treatment as part of the ongoing global study, Dr.. Perrin is optimistic that the promising results will last. “It is very important that you have options for patients whose lifeline in the fight against COVID-19 is running out. Individuals have responded well to this treatment, and the Texas Heart Institute stands ready to help save the lives of those who are running out of hope.. .

1. 18 years or older
2. The patient is confirmed to have SARS-COV 2 by real-time reverse transcription polymerase chain reaction (RT-PCR) assay or other diagnostic test
3. Patient requiring mechanical support for breathing with moderate to severe acute respiratory distress syndrome (ARDS) as determined by criteria adapted from the Berlin Standards, including COVID confirmed in chest radiography or computed tomography (CT).

Tags: acute respiratory distress syndrome, screening, heart disease, cardiovascular disease, cardiovascular surgery, cytology, computed tomography, diagnosis, education, gene therapy, heart, hospital, inflammation, lungs, medicine, stem cells Intermediate, placebo, polymerase, polymerase chain reaction, research, respiratory, running, severe acute respiratory, stem cells, surgery, syndrome, transcription, ventilator

In this interview, News-Medical speaks with Dr.. Christina Branco from Breast Cancer has now reported the spread of breast cancer cells to the lungs.

In this interview, Professor Paul Tessar and Kevin Allan spoke to News-Medical about how low oxygen levels damage the brain..

In this interview, Dr.. Yinang Jiang discusses ACROBiosystems’ efforts and efforts in combating COVID-19 and researching a vaccine

Medical news. NET provides this medical information service according to
These terms and conditions.
Please note that medical information is found
This site is designed to support the relationship, not replace it
Between the patient and the physician / physician and the medical advice they may provide.

We use cookies to improve your experience. By continuing to browse this site, you agree to our use of cookies.
More information.

Mesoblast, Novartis, and ASX: MSB